Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
Study sponsor: Vaxcyte, Inc. · PCVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-08-25Actual
Enrollment · participants802Actual
Source updated2025-09-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.